Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Zhou M, Venkata PP, Viswanadhapalli S, Palacios B, Alejo S, Chen Y, He Y, Pratap UP, Liu J, Zou Y, Lai Z, Suzuki T, Brenner AJ, Tekmal RR, Vadlamudi RK, Sareddy GR. Zhou M, et al. Among authors: alejo s. Breast Cancer Res Treat. 2021 Jan;185(2):343-357. doi: 10.1007/s10549-020-05963-1. Epub 2020 Oct 14. Breast Cancer Res Treat. 2021. PMID: 33057995
KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Venkata PP, Chen Y, Alejo S, He Y, Palacios BE, Loeffel I, Liu J, Pratap UP, Gray G, Achuthan Pillai SM, Zou Y, Lai Z, Suzuki T, Viswanadhapalli S, Palakurthi S, Tekmal RR, Vadlamudi RK, Kost E, Sareddy GR. Venkata PP, et al. Among authors: alejo s. Cancer Lett. 2022 Jan 1;524:219-231. doi: 10.1016/j.canlet.2021.10.019. Epub 2021 Oct 18. Cancer Lett. 2022. PMID: 34673129 Free PMC article.
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, Chen Y, Jayamohan S, Pratap UP, Clarke K, Zou Y, Lv Y, Weldon K, Viswanadhapalli S, Lai Z, Ye Z, Chen Y, Gilbert AR, Suzuki T, Tekmal RR, Zhao W, Zheng S, Vadlamudi RK, Brenner AJ, Sareddy GR. Alejo S, et al. Neuro Oncol. 2023 Jul 6;25(7):1249-1261. doi: 10.1093/neuonc/noad018. Neuro Oncol. 2023. PMID: 36652263 Free PMC article.
Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP, Jayamohan S, He Y, Alejo S, Johnson JD, Palacios BE, Pratap UP, Chen Y, Liu Z, Zou Y, Lai Z, Suzuki T, Viswanadhapalli S, Weintraub ST, Palakurthi S, Valente PT, Tekmal RR, Kost ER, Vadlamudi RK, Sareddy GR. Venkata PP, et al. Among authors: alejo s. Cancer Lett. 2023 Oct 28;575:216383. doi: 10.1016/j.canlet.2023.216383. Epub 2023 Sep 14. Cancer Lett. 2023. PMID: 37714256
Crucial roles of the BRCA1-BARD1 E3 ubiquitin ligase activity in homology-directed DNA repair.
Wang M, Li W, Tomimatsu N, Yu CH, Ji JH, Alejo S, Witus SR, Alimbetov D, Fitzgerald O, Wu B, Wang Q, Huang Y, Gan Y, Dong F, Kwon Y, Sareddy GR, Curiel TJ, Habib AA, Hromas R, Dos Santos Passos C, Yao T, Ivanov DN, Brzovic PS, Burma S, Klevit RE, Zhao W. Wang M, et al. Among authors: alejo s. Mol Cell. 2023 Oct 19;83(20):3679-3691.e8. doi: 10.1016/j.molcel.2023.09.015. Epub 2023 Oct 4. Mol Cell. 2023. PMID: 37797621 Free PMC article.
KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer.
Chen Y, Johnson JD, Jayamohan S, He Y, Venkata PP, Jamwal D, Alejo S, Zou Y, Lai Z, Viswanadhapalli S, Vadlamudi RK, Kost E, Sareddy GR. Chen Y, et al. Among authors: alejo s. Mol Carcinog. 2024 Oct;63(10):2026-2039. doi: 10.1002/mc.23792. Epub 2024 Jul 11. Mol Carcinog. 2024. PMID: 38990091
20 results